Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by Nokamperon Jan 05, 2021 3:31pm
372 Views
Post# 32225848

RE:When is this going to blow up?

RE:When is this going to blow up?Excellent post on Yahoo from Wade, hold on to your share.

''To dumb it down a bit...think of it this way MMEDF shareholders. Currently there are two "stores" at which to purchase MindMed shares: (1) the NEO/OTC open market; or (2) the bought deal via CG, CIBC, etc. (which has 18-20M shares to sell). If the sale price at one store is higher than the sale price at another store, all of the relevant customers will flock to store #2 (or vice-versa). In our case, as small retail investors most of us do not have access to store #2 (the bought deal). However, most high net worth investors or institutional investors do have access to store #2, and thus will not be purchasing at store #1 (NEO/OTC- the open market) unless the price offered at store #1 falls below the price offered at store #2 (which equals the bought deal price of USD $3.45 - minus the value of the associated 1/2 per share warrant). This is the primary reason why the volume has been so much lower since the bought deal as announced. Most (virtually all) savvy/sophisticated investors are choosing to buy at store #2 (bought deal) at the USD $3.45 per share + a 1/2 share warrant (option) exercisable for 3 years at an exercise price of approximately USD $4.54, instead of buying at store #1 (the NEo/OTC- open market) for the current trading price. This may seem counter-intuitive, but is on account of the value the HNW/institutional investors are placing on the accompanying 1/2 share warrant (again, good for 3 years with a USD $4.54 exercise price). Once the bought deal closes and all shares have been placed by CG, CIBC, and the other underwriter, then store #2 closes and any HNW/institutional investor looking to take a position in MindMed can only do so at store #1. And walla...the volume will magically return. After that...with ETFs, uplist to Nasdaq and investment thresholds met for larger institutional investors (think $5 and $10 per share traditionally) wherein they will take larger positions decreasing MindMed's float while a whole new crop of retail investors gets a crack at the stock...and you can see why now would be a very, very, bad time to sell. As others have said...you'll thank me later.
<< Previous
Bullboard Posts
Next >>